1. Home
  2. RENX vs ENSC Comparison

RENX vs ENSC Comparison

Compare RENX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.13

Market Cap

2.0M

Sector

N/A

ML Signal

N/A

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.50

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
ENSC
Founded
2021
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RENX
ENSC
Price
$0.13
$0.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.1M
10.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.31
52 Week High
$0.35
$5.29

Technical Indicators

Market Signals
Indicator
RENX
ENSC
Relative Strength Index (RSI) 41.22 43.83
Support Level N/A $0.31
Resistance Level $0.17 $0.70
Average True Range (ATR) 0.04 0.09
MACD -0.00 0.04
Stochastic Oscillator 2.52 38.54

Price Performance

Historical Comparison
RENX
ENSC

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: